Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Kang JW, Khatib LA, Heston MB, Dilmore AH, Labus JS, Deming Y, Schimmel L, Blach C, McDonald D, Gonzalez A, Bryant M, Ulland TK, Johnson[...]

Wu Y, Meng M, Liu Y, Zeng R, Feng J, Lian Q, Ma Y, Zhang L, Huang W, Leung FW, Duan C, Sha W, Chen[...]

Aldrian D, Pollio A, Mayerhofer C, Diederen K, Jacobs JP, Pai N, Szamosi JC, Hart L, Turner D, Del Chierico F, Cardile S, Grigoryan Z,[...]